MGA271

Product NameMGA271
CAS1353485-38-7
CBNumberCB13303237
MW0
EINECS-0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	M6030H73N9
NCI Drug Dictionary	enoblituzumab

MGA271 Price

Product number	Packaging	Price	Product description	Buy
Biosynth CLA1041	1mg	$1375	Enoblituzumab	Buy
Biosynth CLA1041	5mg	$2406.25	Enoblituzumab	Buy
Biosynth CLA1041	10mg	$4042.5	Enoblituzumab	Buy
ChemScene CS-0105063	1mg	$379	Enoblituzumab 99.16%	Buy
ChemScene CS-0105063	5mg	$986	Enoblituzumab 99.16%	Buy

MGA271 Chemical Properties,Usage,Production

Uses

Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators[1].

in vivo

Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a C_max of 43 mg/mL in mice (mCD16^-/^-hCD16A⁺) that murine CD16 gene knocked out and are transgenic for human CD16A-158F^[3].
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma^[3].

Animal Model:	mCD16^-/^-hCD16A⁺ mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)^[3]
Dosage:	1 mg/kg, 5 mg/kg, 10 mg/kg
Administration:	Intravenous injection; once weekly; 5 weeks
Result:	Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment. Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group.

References

[1] Hińcza-Nowak K, et al. Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy. Genes (Basel). 2021 Sep 28;12(10):1534. DOI:10.3390/genes12101534
[2] Chapoval, et al. Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. Russ J Bioorg Chem 45, 321–334 (2019).
[3] Loo D, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834-45. DOI:10.1158/1078-0432.CCR-12-0715

Preparation Products And Raw materials

MGA271 Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
BOC Sciences	1-631-485-4226; 16314854226	info@bocsci.com	United States	9920	65
Shanghai YuanYe Biotechnology Co., Ltd.	18916372613	yanzihan@shyuanye.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7999	62
TargetMol Chemicals Inc.	+1-781-999-5354; +1-00000000000	marketing@targetmol.com	United States	32430	58
Guangzhou Hongyuan Chemical Co.,Ltd	15817493340	981810490@qq.com	China	1577	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10300	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24951	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7353	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58

View Latest Prices from MGA271 manufacturers

1353485-38-7, MGA271Related Search

Send Inquiry